Cancer Genetics Inc. (CGIX) Director John Pappajohn Buys 31,100 Shares of Stock
Cancer Genetics Inc. (NASDAQ:CGIX) Director John Pappajohn purchased 31,100 shares of Cancer Genetics stock in a transaction dated Monday, November 14th. The shares were bought at an average price of $1.48 per share, for a total transaction of $46,028.00. Following the acquisition, the director now owns 2,320,709 shares in the company, valued at $3,434,649.32. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cancer Genetics Inc. (NASDAQ:CGIX) traded up 4.687% during trading on Thursday, reaching $1.675. The company’s stock had a trading volume of 123,103 shares. The company’s market capitalization is $31.64 billion. Cancer Genetics Inc. has a 1-year low of $1.10 and a 1-year high of $3.82. The company’s 50-day moving average is $1.55 and its 200-day moving average is $1.96.
Cancer Genetics (NASDAQ:CGIX) last posted its earnings results on Thursday, November 10th. The company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. The company had revenue of $6.80 million for the quarter, compared to analyst estimates of $6.93 million. Cancer Genetics had a negative return on equity of 63.26% and a negative net margin of 74.07%. Cancer Genetics’s revenue was up 70.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.56) earnings per share. Equities analysts anticipate that Cancer Genetics Inc. will post ($1.17) EPS for the current year.
A number of hedge funds have recently bought and sold shares of CGIX. Bridger Management LLC purchased a new stake in Cancer Genetics during the first quarter valued at $149,000. Eagle Global Advisors LLC increased its stake in shares of Cancer Genetics by 69.3% in the second quarter. Eagle Global Advisors LLC now owns 84,320 shares of the company’s stock valued at $168,000 after buying an additional 34,510 shares in the last quarter. Sabby Management LLC increased its stake in shares of Cancer Genetics by 145.5% in the second quarter. Sabby Management LLC now owns 199,580 shares of the company’s stock valued at $397,000 after buying an additional 118,280 shares in the last quarter. Fairbanks Capital Management Inc. increased its stake in shares of Cancer Genetics by 0.9% in the third quarter. Fairbanks Capital Management Inc. now owns 235,170 shares of the company’s stock valued at $411,000 after buying an additional 2,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Cancer Genetics by 3.3% in the second quarter. Vanguard Group Inc. now owns 326,966 shares of the company’s stock valued at $651,000 after buying an additional 10,328 shares in the last quarter. 11.08% of the stock is currently owned by institutional investors.
A number of analysts recently issued reports on CGIX shares. Zacks Investment Research raised Cancer Genetics from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Tuesday. Rodman & Renshaw started coverage on Cancer Genetics in a research report on Monday, September 26th. They set a “buy” rating and a $6.00 price objective for the company. Finally, HC Wainwright started coverage on Cancer Genetics in a research report on Tuesday, September 27th. They set a “buy” rating and a $6.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $7.19.
About Cancer Genetics
Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.
Receive News & Stock Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related stocks with our FREE daily email newsletter.